


This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims

1. (*original*) A compound of Formula I:



wherein

Q is



R¹, R² and R³ are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

X and Y are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon

atoms or alkanesulfonamido of 1 to 6 carbon atoms, or X and Y, taken together, form $-N=C(R^4)-C(R^5)=N-$, $-N=C(R^4)-C(R^6)=CH-$, $-N=C(R^4)-N=CH-$, $-N=C(R^4)-O-$, $-NH-C(R^7)=N-$ or $-NH-C(R^8)=CH-$;

R^4 and R^5 are, independently, hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R^6 is hydrogen or alkyl of 1 to 6 carbon atoms;

R^7 is hydrogen, halo, trifluoromethyl, pentafluoroethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;

R^8 is hydrogen, halo, trifluoromethyl, pentafluoroethyl, or alkyl of 1 to 6 carbon atoms;

Z is O, S, or NR^9 , in which R^9 is hydrogen or alkyl of 1 to 6 carbon atoms;

n is an integer 0, 1, or 2;


m is an integer from 1 to 4, provided that $m + n \leq 4$ and that when $m = n = 2$, and Q is b then X and Y are not $NH-C(R^8)=CH-$; and

p is an integer from 1 to 3, provided that $p + n$ is 2 or 3;

or a pharmaceutically acceptable salt thereof.

2. *(original)* A compound according to claim 1, wherein X and Y, taken together, form $-N=C(R^4)-C(R^6)=CH-$ or a pharmaceutically acceptable salt thereof.

3. *(original)* A compound according to claim 1, wherein Q is




a

or a pharmaceutically acceptable salt thereof.

4. *(original)* A compound according to claim 1, wherein Z is NR⁹ or a pharmaceutically acceptable salt thereof.
5. *(original)* A compound according to claim 1, wherein n is 0 or 1 or a pharmaceutically acceptable salt thereof.
6. *(original)* A compound according to claim 1, wherein m is 1 to 3 or a pharmaceutically acceptable salt thereof.
7. *(original)* A compound according to claim 1, wherein p is 1 or 2 or a pharmaceutically acceptable salt thereof.
8. *(original)* A compound according to claim 1, wherein R¹ is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
9. *(original)* A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
10. *(original)* A compound according to claim 1, wherein R⁴ and R⁵ are independently hydrogen, amino or alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.
11. *(original)* A compound according to claim 1, wherein R⁷ and R⁸ are independently selected from hydrogen, trifluoromethyl, pentafluoroethyl or alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable salt thereof.

12. *(original)* A compound according to claim 1, wherein R^6 is hydrogen or alkyl of 1 to 3 carbon atoms, Z is NR^9 in which R^9 is hydrogen or alkyl of 1 to 3 carbon atoms, n is 0 or 1, m is 1 to 3 and p is 1 or 2 or a pharmaceutically acceptable salt thereof.

13. *(original)* A compound of Formula Ia:



Ia

or a pharmaceutically acceptable salt thereof.

14. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

15. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

16. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(6-fluoro-1H-indol-3-ylmethyl)-piperidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

17. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.

18. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(5-fluoro-1-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
19. *(original)* A compound according to claim 1, wherein said compound is 2-({4-[(6-Fluoro-1H-indol-1-yl)methyl]piperidin-1-yl}-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
20. *(original)* A compound according to claim 1, wherein said compound is 2-({4-[(6-Fluoro-1H-indol-1-yl)methyl]piperidin-1-yl}-8-ethyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
21. *(original)* A compound according to claim 1, wherein said compound is 1-[(1-{[8-Methyl-2,3-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl)methyl]piperidin-4-yl}-1H-indole-6-carbonitrile or a pharmaceutically acceptable salt thereof.
22. *(original)* A compound according to claim 1, wherein said compound is 2-[3-(6-Fluoro-indol-1-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
23. *(original)* A compound according to claim 1, wherein said compound is 2-{3-[2-(6-Fluoro-indol-1-yl)-ethyl]-azetidin-1-ylmethyl}-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
24. *(original)* A compound according to claim 1, wherein said compound is 1-{2-[1-(8-Methyl-2,3-dihydro-[1,4]-dioxino[2,3-f]quinolin-2-ylmethyl)-azetidin-3-yl]-ethyl}-1H-indole-6-carbonitrile or a pharmaceutically acceptable salt thereof.

25. *(original)* A compound according to claim 1, wherein said compound is 8-Methyl-2-[3-(5-methyl-1H-indol-3-ylmethyl)-azetidin-1-ylmethyl]-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
26. *(original)* A compound according to claim 1, wherein said compound is the S enantiomer at the 2-aminomethyl-2,3-dihydro-1,4-benzodioxan moiety, substantially free of the R enantiomer of said compound.
27. *(withdrawn)* A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction, comprising the step of:
administering to said subject suffering from said condition a therapeutically effective amount of a compound according to claim 1.
28. *(withdrawn)* A method according to claim 27, wherein the condition is depression.
29. *(withdrawn)* A method according to claim 27, wherein the condition is selected from the group consisting of obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
30. *(original)* A pharmaceutical composition, comprising:
an effective amount of a compound according to claim 1; and
a pharmaceutically acceptable carrier or excipient.